Jeremy Stapleton, DO
Gastroenterology · Charleston, WVNPI 1609905462
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 432 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 25 manufacturers reported payments, led by AbbVie at 26.6% of the total.
Across 432 payments — averaging $15.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Takeda Pharmaceuticals U.S.A., Inc.$1K
- Pfizer$827
- Gilead$677
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$567
- Johnson & Johnson$388
- plus $1K from 19 others
What the payments were for
- Food & beverage$6,655100%
- Gifts$290%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 130 | $1,777 |
| Takeda Pharmaceuticals U.S.A., Inc. | 69 | $1,284 |
| Pfizer | 48 | $827 |
| Gilead | 49 | $677 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 47 | $567 |
| Johnson & Johnson | 22 | $388 |
| Ardelyx, Inc. | 8 | $137 |
| Aimmune Therapeutics, Inc. | 6 | $113 |
| Bristol Myers Squibb | 7 | $109 |
| Phathom Pharmaceuticals, Inc. | 8 | $106 |
| Regeneron Healthcare Solutions, Inc. | 5 | $94 |
| QOL Medical, LLC | 4 | $94 |
| Redhill Biopharma Inc. | 6 | $83 |
| Nestle Healthcare Nutrition Inc. | 2 | $75 |
| Merck | 4 | $60 |
| Axonics, Inc. | 3 | $49 |
| Shionogi Inc | 2 | $40 |
| Novo Nordisk | 2 | $35 |
| Lilly USA, LLC | 2 | $33 |
| Braintree Laboratories, Inc. | 2 | $29 |
| Alnylam Pharmaceuticals Inc. | 1 | $29 |
| Evoke Pharma, Inc. | 2 | $27 |
| Celltrion USA Inc. | 1 | $23 |
| Actelion Pharmaceuticals US, Inc. | 1 | $14 |
| Boehringer Ingelheim | 1 | $14 |
How this compares
$6,685 in reported general payments places this provider in the 75th percentile of 72 gastroenterology providers in West Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 68 | $1,783,580 |
| Humira(Cf) PenAdalimumab | 54 | $438,540 |
| CreonLipase/Protease/Amylase | 41 | $179,212 |
| RemicadeInfliximab | 23 | $163,446 |
| ZenpepLipase/Protease/Amylase | 27 | $158,560 |
| XifaxanRifaximin | 46 | $148,076 |
| EntyvioVedolizumab | 13 | $117,937 |
| LinzessLinaclotide | 80 | $101,615 |
| PentasaMesalamine | 12 | $40,036 |
| IbsrelaTenapanor Hcl | 13 | $35,508 |
| TrulancePlecanatide | 33 | $34,478 |
| Mesalamine ErMesalamine | 65 | $25,849 |
| ViberziEluxadoline | 11 | $16,574 |
| MotegrityPrucalopride Succinate | 14 | $14,580 |
| Sucralfate | 150 | $12,267 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara, Remicade | $388 | $1,947,02791 claims |
| AbbVieCreon, Linzess, Viberzi | $1,777 | $297,401132 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance | $567 | $182,55479 claims |
| Aimmune Therapeutics, Inc.Zenpep | $113 | $158,56027 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Entyvio, Motegrity | $1,284 | $132,51627 claims |
| Ardelyx, Inc.Ibsrela | $137 | $35,50813 claims |
| Redhill Biopharma Inc.Movantik | $83 | $10,15917 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 72 gastroenterology providers in West Virginia.
Other gastroenterology in Charleston
- Megan HansonCharleston$11K
- Muhammad BashirCharleston$7K
- Jeremy CumberledgeCharleston$7K
- Marc SubikCharleston$2K
- Mohamad SankariCharleston$1K
- Roberta HunterCharleston$769
- Vishnu Vardhan Reddy NaravadiCharleston$285
- Jennifer VeverkaMorgantown$283K
- Shailendra SinghMorgantown$187K
- Mohamad HaffarSouth Charleston$118K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.